REG-Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Key Highlights
- ➤FDA clears Privosegtor IND for acute multiple sclerosis relapses
- ➤Oculis can cross-reference data from its existing ophthalmology-related IND
- ➤FDA supports trials including optic neuritis and ambulatory relapses
- ➤Privosegtor Phase 2 ACUITY trial improved visual function and preserved retinal integrity
- ➤Oculis schedules R&D Day for December 8, 2026
Expert Statements
Riad Sherif, Chief Executive Officer of Oculis
“This IND clearance marks a pivotal new era for Oculis in neurology as we advance Privosegtor from optic neuritis into acute MS relapses, addressing a high-unmet-need setting with no currently approved neuroprotective therapies”
Riad Sherif, Chief Executive Officer of Oculis
“Because optic neuritis is a common manifestation of MS relapse, our positive Phase 2 ACUITY results give us confidence in Privosegtor’s potential to limit neuroaxonal damage and support functional recovery following an acute attack.”
Riad Sherif, Chief Executive Officer of Oculis
“Building on the foundation of our PIONEER registrational program in optic neuritis, we are well-positioned to accelerate the clinical development of Privosegtor in this new indication.”
Riad Sherif, Chief Executive Officer of Oculis
“We value the FDA’s constructive engagement and are excited about the meaningful impact Privosegtor could have on patients experiencing optic neuritis and other MS relapses.”
Amit Bar-Or, Professor of Neurology at the Perelman School of Medicine, University of Pennsylvania
“Even with effective immunomodulating therapies, many people with MS still experience relapses, and recovery from them is often incomplete.”
Amit Bar-Or, Professor of Neurology at the Perelman School of Medicine, University of Pennsylvania
“A treatment that protects neurons and axons during an acute relapse would fill a gap that no current care addresses.”
Amit Bar-Or, Professor of Neurology at the Perelman School of Medicine, University of Pennsylvania
“I am encouraged to see Privosegtor moving toward clinical development in acute MS relapses and beyond and look forward to seeing how the data evolve.”
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis
Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies
Get started
Create a free account to read the full story.
